Understanding Pomalyst® (pomalidomide) capsules

Pomalyst® (pomalidomide) is an immunomodulatory agent approved by the U.S. Food and Drug Administration (FDA) in 2013 for the treatment of adult patients with relapsed and refractory myeloma who have received at least 2 prior therapies, including Revlimid® (lenalidomide) and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of the last therapy. Pomalyst is an oral medication taken by mouth in capsule form.